PTGDR2 Identifies super-responders to Benralizumab and Mepolizumab in severe asthma

Biological therapies targeting the interleukin-5 (IL-5) pathway are effective in severe eosinophilic asthma, but treatment responses remain heterogeneous, and reliable predictors of response are lacking. Transcriptomic approaches may help identify molecular signatures associated with clinical outcomes. We conducted a prospective real-world study including 46 patients with severe eosinophilic asthma treated with mepolizumab or benralizumab. Peripheral blood RNA sequencing was performed in a subset of 25 patients at baseline and after 6 months of treatment. Differential gene expression and pathway enrichment analyses were used to characterise shared and treatment-specific transcriptomic effects. Clinical response was assessed using the FEOS score, including identification of super-responders. Both biologics induced significant clinical improvements, including reductions in exacerbations and oral corticosteroid use, as well as improved asthma control and lung function. Transcriptomic analyses revealed a shared molecular signature characterised by downregulation of type 2 inflammatory pathways. Benralizumab was associated with deeper suppression of eosinophil-related transcripts. Benralizumab-specific differentially expressed genes (DEGs), which were predominantly downregulated, were enriched in PI3K/AKT and receptor tyrosine kinase signalling pathways. In contrast, mepolizumab-specific DEGs, also predominantly downregulated, were enriched in immune-regulatory and apoptosis-related pathways. PTGDR2 expression was validated by qPCR and showed significant treatment-associated downregulation. Baseline PTGDR2 expression was associated with super-response and outperformed conventional biomarkers. IL-5 neutralisation and IL-5 receptor blockade induced broadly shared but distinct transcriptomic programs in severe eosinophilic asthma. PTGDR2 may represent a candidate biomarker associated with treatment response. These findings provide mechanistic insights and suggest potential applications for biomarker-guided patient stratification.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2026-11-19
DOI
https://doi.org/10.1183/23120541.00479-2026
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PTGDR2 Identifies super-responders to Benralizumab and Mepolizumab in severe asthma

Catalina Sanz, Cristina Martín, Asunción Garcı́a-Sánchez, María Gil‐Melcón et al.
ERJ Open Research
Asthma and respiratory diseases
article

PTGDR2 Identifies super-responders to Benralizumab and Mepolizumab in severe asthma

Catalina Sanz, Cristina Martín, Asunción Garcı́a-Sánchez, María Gil‐Melcón, Cristina Bajo-Santos, Milagros Lázaro‐Sastre, Miguel Estravís, Juan Carlos Triviño, María Isidoro‐García, Santiago Bueno-Fortes, Ignacio J. Davila, Emma Moreno‐Jimenez, Francisco Javier Muñoz‐Bellido, Manuel Gómez-García, Elena Curto, Natalia Morgado
article en

Abstract

Biological therapies targeting the interleukin-5 (IL-5) pathway are effective in severe eosinophilic asthma, but treatment responses remain heterogeneous, and reliable predictors of response are lacking. Transcriptomic approaches may help identify molecular signatures associated with clinical outcomes. We conducted a prospective real-world study including 46 patients with severe eosinophilic asthma treated with mepolizumab or benralizumab. Peripheral blood RNA sequencing was performed in a subset of 25 patients at baseline and after 6 months of treatment. Differential gene expression and pathway enrichment analyses were used to characterise shared and treatment-specific transcriptomic effects. Clinical response was assessed using the FEOS score, including identification of super-responders. Both biologics induced significant clinical improvements, including reductions in exacerbations and oral corticosteroid use, as well as improved asthma control and lung function. Transcriptomic analyses revealed a shared molecular signature characterised by downregulation of type 2 inflammatory pathways. Benralizumab was associated with deeper suppression of eosinophil-related transcripts. Benralizumab-specific differentially expressed genes (DEGs), which were predominantly downregulated, were enriched in PI3K/AKT and receptor tyrosine kinase signalling pathways. In contrast, mepolizumab-specific DEGs, also predominantly downregulated, were enriched in immune-regulatory and apoptosis-related pathways. PTGDR2 expression was validated by qPCR and showed significant treatment-associated downregulation. Baseline PTGDR2 expression was associated with super-response and outperformed conventional biomarkers. IL-5 neutralisation and IL-5 receptor blockade induced broadly shared but distinct transcriptomic programs in severe eosinophilic asthma. PTGDR2 may represent a candidate biomarker associated with treatment response. These findings provide mechanistic insights and suggest potential applications for biomarker-guided patient stratification.

ERJ Open Research
Universidad de Salamanca (ES), Complejo Hospitalario de Salamanca (ES), Instituto de Investigación Biomédica de Salamanca (ES), Sistemas Genómicos (ES)
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon